Biogen News and Research

RSS
Biogen Idec and Cardiokine terminate lixivaptan collaboration

Biogen Idec and Cardiokine terminate lixivaptan collaboration

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Autism Consortium begins new therapeutic initiative on Translational Medicine

Autism Consortium begins new therapeutic initiative on Translational Medicine

ImmunoGen first quarter net loss increases to $12.9 million

ImmunoGen first quarter net loss increases to $12.9 million

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Biogen 2010 third quarter revenue increase 5% to $1.2 billion

Biogen 2010 third quarter revenue increase 5% to $1.2 billion

Maven Semantic updates Lymphocyte Cell Biology research database

Maven Semantic updates Lymphocyte Cell Biology research database

Biogen, Genentech announce new structure of anti-CD20 collaboration

Biogen, Genentech announce new structure of anti-CD20 collaboration

Biogen, Elan announce clinical utility data of two-step ELISA to detect anti-JCV antibodies

Biogen, Elan announce clinical utility data of two-step ELISA to detect anti-JCV antibodies

Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study

Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

Knopp Neurosciences forms new parent entity

Knopp Neurosciences forms new parent entity

Top biopharma leaders to share strategies at Windhover's 2nd PharmAsia Summit

Top biopharma leaders to share strategies at Windhover's 2nd PharmAsia Summit

XenoPort to present XP23829 preclinical data at ECTRIMS meeting

XenoPort to present XP23829 preclinical data at ECTRIMS meeting

Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress

Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress

Biogen Idec concurs with FDA on safety monitoring for Gilenya through REMS

Biogen Idec concurs with FDA on safety monitoring for Gilenya through REMS

EHSI applauds Sen. Specter's support for Stem Cell Research Advancement Act

EHSI applauds Sen. Specter's support for Stem Cell Research Advancement Act

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

Santarus expands development pipeline, adds two novel biologic drug candidates

Santarus expands development pipeline, adds two novel biologic drug candidates

iPierian raises $28 million from Series B equity financing closure

iPierian raises $28 million from Series B equity financing closure